Skip to main content
Celyad Oncology SA logo

Celyad Oncology SA — Investor Relations & Filings

Ticker · CYAD ISIN · BE0974260896 LEI · 549300ORR0M8XF56OI64 BR Professional, scientific and technical activities
Open in API
Filings indexed 923 across all filing types
Latest filing 2025-04-18 Management Reports
Country BE Belgium
Listing BR CYAD

About Celyad Oncology SA

https://celyad.com/

Celyad Oncology is a biotechnology company primarily focused on unlocking the potential of its intellectual property in the field of cell therapy. The company discovers and develops innovative technologies for Chimeric Antigen Receptor T-cell (CAR-T) therapies aimed at treating cancer. Its differentiated strategy includes the advancement of proprietary technology platforms and CAR T-cell candidates designed to broaden the range of treatable cancer indications and overcome the main limitations of existing CAR T-cell therapies.

Recent filings

Filing Released Lang Actions
Rapport_Special_2025_FR.pdf
Management Reports Classification · 100% confidence The document is a 'Rapport Spécial du Conseil d'Administration' (Special Report of the Board of Directors) prepared in accordance with Article 7:228 of the Belgian Code of Companies and Associations. This specific legal requirement is triggered when a company's net assets fall below a certain threshold of its share capital, necessitating a report to shareholders regarding the company's continuity. This document is a formal governance and management report detailing the financial situation, the causes of losses, and the board's proposed measures for business continuity. It is not an annual report (10-K), an earnings release (ER), or a simple announcement (RPA), but rather a specific governance-related report required by law for shareholder meetings.
2025-04-18 French
CELYAD - AGM 20 May 2025 - Minutes ENG.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'MINUTES OF THE ORDINARY GENERAL MEETING OF SHAREHOLDERS' and details the proceedings, agenda items, and specific voting results for each resolution (e.g., approval of accounts, discharge of directors, remuneration report). Since it provides the official results of the votes taken at the Annual General Meeting, it falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2025-04-18 English
Celyad_PV_AGO_20_mai_2025_FR.signed.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a 'Procès-verbal' (minutes) of an Annual General Meeting (AGM) held on May 20, 2025. It details the attendance, the agenda items (such as approval of annual accounts, remuneration reports, and discharge of directors), and the specific voting results for each resolution. Since it provides the official record of the decisions and voting outcomes of the AGM, it is classified as a Declaration of Voting Results & Voting Rights Announcement.
2025-04-18 French
Celyad Oncology SA - AGE Procès-verbal signé 20 mai 2025.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal notarial record of an Extraordinary General Meeting (Assemblée Générale Extraordinaire) for 'Celyad Oncology'. It details the agenda, quorum, and the specific voting results for several resolutions regarding capital reduction and statutory amendments. Since it provides the official results of shareholder votes at a general meeting, it falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2025-04-18 French
CELYAD - AGM & EGM May 2025 - Information to shareholders - ENG.Final.pdf
AGM Information Classification · 98% confidence The document is an official notice to shareholders regarding their rights to include items on the agenda and submit written questions for the upcoming Ordinary and Extraordinary General Meetings of Celyad Oncology SA. This type of document is a standard proxy-related communication sent to shareholders to facilitate their participation in the voting process, which falls under the Proxy Solicitation & Information Statement category.
2025-04-18 English
CELYAD - AGO et AGE mai 2025 - Informations aux actionnaires - FR.Final.pdf
AGM Information Classification · 98% confidence The document is a formal notice to shareholders regarding their rights to propose agenda items and submit written questions for the upcoming Ordinary and Extraordinary General Meetings of Celyad Oncology SA. This type of document is a standard component of the proxy solicitation process, providing shareholders with the necessary information to participate in the governance of the company ahead of a meeting. It falls under the category of Proxy Solicitation & Information Statement.
2025-04-18 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.